Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
FLO enters the final stretch before its November earnings with a consistent message from the Street: things are worse than they looked six months ago, and the short side remains well-anchored at 22% of the free float.
The analyst story has turned uniformly negative this week. BNP Paribas cut its target to $5.00 from $6.50 on Wednesday, keeping its Underperform rating intact. Jefferies followed the same day, trimming to $6.00 from $7.00 while holding at Hold. Both actions came after a year of almost unbroken target reductions across the coverage universe. Deutsche Bank moved from $11 to $7 in March. Stephens slashed from $11 to $6 by August. The mean target now stands at $7.70, implying around 34% upside from the current $5.74 close, but that consensus reflects a Street that has been consistently too optimistic on this name. The BNP target of $5.00 is already below where the stock trades, a rare signal that at least one analyst thinks fair value is in the rearview mirror.
The bear case is hard to argue with on the numbers. Second-quarter adjusted EPS of $0.21 missed expectations. Net sales fell 4.0% to $1.193 billion, driven by a 5.8% volume decline that points to genuine demand erosion rather than pricing noise. Management then lowered full-year guidance on sales, EBITDA, and EPS. The bull case rests on Dave's Killer Bread continuing to take share and a dividend yield that the bears peg at nearly 14% on the current price. The catch: the payout ratio runs around 125% on an EPS basis. Bulls argue the free-cash-flow payout is closer to 80%, leaving a thin but real buffer. With EV/EBITDA at 7.5x and a price-to-book barely above 0.9x, valuation has compressed substantially, though the factor picture is uniformly cautious. EPS momentum ranks in the bottom quintile on both 30-day and 90-day windows. The short score sits at 74.2, near the top of its recent range, placing the stock in the second percentile for the short score rank across the universe.
Short interest reinforces the bearish lean. At 22% of the free float, roughly 46.6 million shares are short, and that number has crept up about 1.3% over the past month. The FINRA fortnightly settlement print put official short interest at 46.5 million shares with a 5.6 days-to-cover reading, leaving anyone who needed to cover in a hurry exposed to a meaningful unwind. Cost to borrow has eased considerably from a September peak near 2.1%, now back around 1.0%, which removes one friction point for holding short positions. Availability is comfortable at 115%, meaning about 141 million shares remain available to borrow relative to the outstanding short position, well clear of any squeeze pressure. The borrow market is not tightening; shorts can sit with relatively little cost.
Options positioning has shifted sharply toward calls. The put/call ratio has dropped to 0.24, the lowest reading of the past 52 weeks and more than one standard deviation below its 20-day average of 0.32. That is the opposite of what might be expected given the fundamental backdrop. The PCR was running closer to 0.50 through August and September, and its collapse in recent weeks suggests either active call buying or a significant reduction in put hedges. It is worth noting this happens while the stock is trading near $5.74, down 8.5% over the past month and roughly 44% year-to-date. The divergence between an extreme-low put/call ratio and high short interest is the genuine tension in this setup.
BlackRock stands out in the ownership picture, building a position to 16.3% of shares as of the end of September, up from around 11.6% earlier in the year according to the most recent 13G/A filing. Vanguard has also been adding, reaching 6.6% of the class in a July filing, up from 5.1%. Both are passive-style accumulations reflecting the stock's continued presence in index products despite the price decline. There are no 13D activist holders on the register. Fuller & Thaler, an active manager known for behavioral-finance approaches, holds just under 5.2% of shares per the institutional table, with a minimal recent change. Insider activity from the data available is stale at 114 days old: the most material disclosed trade was a 209,000-share open-market sale by Chairman and CEO Ryals McMullian in April at roughly $8.03 per share, a transaction not conducted under a 10b5-1 plan. The CFO bought 5,000 shares at $7.51 in June, a smaller signal of confidence at a price well above today's level.
Retail attention around the stock has picked up recently, with Wikipedia page views running at a z-score of 2.4 against the company's own 90-day history, the highest reading in the tracking window. That kind of spike in attention often accompanies price dislocation and news coverage rather than fundamental change.
The next earnings print is scheduled for 25 November, and given the pattern of the last release, where the stock fell 6.8% on the day before partially recovering, the key question heading into that date is whether volume trends have stabilised or continued to deteriorate at the same pace management signalled in August.
See the live data behind this article on ORTEX.
Open FLO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
